Elanco Animal Health Inc
ELANNYSE
$25.83
↓ -0.5%Jul 17 close · end-of-day
Price
1Y↑ +78.0%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$13.1B
Enterprise Value
$16.6B
P/E
—
P/S
2.7
P/B
2.0
EV/EBITDA
—
PEG
—
FCF Yield
2.4%
Dividend Yield
—
Revenue (TTM)
$4.9B
Net Income (TTM)
-$242.0M
Free Cash Flow (TTM)
$315.0M
Gross Margin
55.1%
Operating Margin
—
Net Margin
-5.0%
ROE
-3.7%
ROIC
—
Debt / Equity
0.6
Net Cash
-$3.6B
Return 1Y
+72.7%
Company profile
Elanco Animal Health Incorporated offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers.
- CEO
- Jeffrey N. Simmons
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 9,800
- Headquarters
- Indiana
- Website
- elanco.com
Management & directors
- Vanhimbergen Robert MEVP and CFO
- Modi Rajeev A.SEE REMARKS
- Simmons Jeffrey NPRESIDENT, CEO AND DIRECTOR
- De Brabander EllenSEE REMARKS
- Bettington Timothy JSEE REMARKS
- Cabral Ramiro MartinSEE REMARKS
- Correia De Simas Jose ManuelSEE REMARKS
- Kinard David SSEE REMARKS
- Mcardle GraceEVP, MANUFACTURING AND QUALITY
- Meer James MCHIEF ACCOUNTING OFFICER
- O'Neill ShivGC AND CORP SEC
Roles derived from SEC Form 4 filings.
Earnings
ELAN Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$1.4B↑ +14.9%
Diluted EPS$0.11↓ -15.4%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $3.3B | $4.8B | $4.4B | $4.4B | $4.4B | $4.7B |
| Gross profit | — | — | — | $2.5B | $2.4B | $2.6B |
| Operating income | — | — | — | — | — | — |
| Net income | -$574.0M | -$483.0M | -$78.0M | -$1.2B | $338.0M | -$232.0M |
| Diluted EPS | -$1.30 | -$0.99 | -$0.16 | -$2.50 | $0.68 | -$0.47 |
| Operating cash flow | -$41.0M | $483.0M | $452.0M | $271.0M | $541.0M | $560.0M |
| Free cash flow | -$176.0M | $324.0M | $281.0M | $131.0M | $394.0M | $284.0M |
| Gross margin | — | — | — | 56.3% | 54.9% | 55.0% |
| Operating margin | — | — | — | — | — | — |
| Net margin | -17.5% | -10.1% | -1.8% | -27.9% | 7.6% | -4.9% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.2B | $1.0B | $1.0B | $1.2B | $1.2B | $1.1B | $1.1B | $1.4B |
| Gross profit | $689.0M | $538.0M | $519.0M | $684.0M | $713.0M | $607.0M | $589.0M | $785.0M |
| Operating income | — | — | — | — | — | — | — | — |
| Net income | -$50.0M | $364.0M | -$8.0M | $67.0M | $11.0M | -$34.0M | -$276.0M | $57.0M |
| Diluted EPS | -$0.10 | $0.73 | -$0.01 | $0.13 | $0.02 | -$0.07 | -$0.55 | $0.11 |
| Operating cash flow | $200.0M | $162.0M | $177.0M | -$4.0M | $237.0M | $219.0M | $108.0M | $13.0M |
| Free cash flow | $166.0M | $120.0M | $130.0M | -$69.0M | $180.0M | $127.0M | $46.0M | -$38.0M |
| Gross margin | 58.2% | 52.2% | 50.9% | 57.3% | 57.5% | 53.4% | 51.5% | 57.3% |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | -4.2% | 35.3% | -0.8% | 5.6% | 0.9% | -3.0% | -24.1% | 4.2% |
Company news
Jul 15, 2026
Jun 30, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-07 | VanHimbergen Robert M· EVP and CFO | Tax withholding | 15,336 | $24.64 | $377,879.04 | filing |
| 2026-05-21 | Pollard-Knight Denise | Award | 4,678 | $0.00 | $0.00 | filing |
| 2026-05-21 | Pollard-Knight Denise | Award | 12,196 | $0.00 | $0.00 | filing |
| 2026-05-21 | Kurzius Lawrence Erik | Award | 4,678 | $0.00 | $0.00 | filing |
| 2026-05-21 | Kurzius Lawrence Erik | Award | 12,196 | $0.00 | $0.00 | filing |
| 2026-05-21 | McDonald Kirk P | Award | 4,678 | $0.00 | $0.00 | filing |
| 2026-05-21 | McDonald Kirk P | Award | 12,196 | $0.00 | $0.00 | filing |
| 2026-05-21 | Herendeen Paul | Award | 4,678 | $0.00 | $0.00 | filing |
| 2026-05-21 | Herendeen Paul | Award | 12,196 | $0.00 | $0.00 | filing |
| 2026-05-21 | Kochevar Deborah Turner | Award | 4,678 | $0.00 | $0.00 | filing |
| 2026-05-21 | HOOVER R DAVID | Award | 4,678 | $0.00 | $0.00 | filing |
| 2026-05-21 | Harrington Michael J | Award | 4,678 | $0.00 | $0.00 | filing |
| 2026-05-21 | Harrington Michael J | Award | 12,196 | $0.00 | $0.00 | filing |
| 2026-05-21 | Anand Kapila K | Award | 4,678 | $0.00 | $0.00 | filing |
| 2026-05-21 | Anand Kapila K | Award | 12,196 | $0.00 | $0.00 | filing |
| 2026-05-21 | Ma Stacey | Award | 4,678 | $0.00 | $0.00 | filing |
| 2026-05-21 | GARCIA ART A | Award | 4,678 | $0.00 | $0.00 | filing |
| 2026-05-21 | GARCIA ART A | Award | 12,196 | $0.00 | $0.00 | filing |
| 2026-05-21 | Ma Stacey | Award | 12,196 | $0.00 | $0.00 | filing |
| 2026-05-15 | Modi Rajeev A.· SEE REMARKS | Buy | 4,911 | $20.35 | $99,938.85 | filing |
| 2026-05-15 | Simmons Jeffrey N· PRESIDENT, CEO AND DIRECTOR | Buy | 4,971 | $20.09 | $99,842.54 | filing |
| 2026-04-01 | de Brabander Ellen· SEE REMARKS | Tax withholding | 20,288 | $23.12 | $469,058.56 | filing |
| 2026-04-01 | de Brabander Ellen· SEE REMARKS | Award | 40,985 | $0.00 | $0.00 | filing |
| 2026-03-03 | Simmons Jeffrey N· PRESIDENT, CEO AND DIRECTOR | Tax withholding | 37,898 | $24.88 | $942,902.24 | filing |
| 2026-03-03 | de Brabander Ellen· SEE REMARKS | Tax withholding | 8,262 | $24.88 | $205,558.56 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.